AGMB AgomAb Therapeutics NV: institutional ownership and insider trading
35 funds reported holding $334M of AgomAb Therapeutics NV in their latest 13F filings; in Q2 2026 funds net bought $33.8M, with 9 new positions and 7 funds selling out; over the last 12 months insiders bought $400K and sold $0 on the open market.
Famous investors holding AGMB
- Two Sigma (Two Sigma Investments): $235K, 0.0% of the portfolio
Largest institutional holders of AGMB
- EQT Fund Management S.a r.l. — $66.7M
- Sanofi (SNY, SNYNF) — $36.1M
- Redmile Group, LLC — $35.5M
- Cormorant Asset Management, LP — $32.0M
- TCG Crossover Management, LLC — $26.7M
- FEDERATED HERMES, INC. (FHI) — $21.0M
- Nantahala Capital Management, LLC — $20.4M
- Casdin Capital, LLC — $20.1M
- FMR LLC — $18.9M
- Andera Partners — $17.1M
Recent AGMB insider trades
- Oct 21, 2026: Epstein David R bought 10,000 shares ($88.8K)
- Oct 8, 2026: Epstein David R bought 5,000 shares ($44.5K)
- Oct 6, 2026: Knotnerus Tim Jasper bought 11,000 shares ($94.4K)
- Oct 6, 2026: Kemula Pierre Thadee Victor bought 10,000 shares ($85.9K)
5%+ owners
- Pontifax VI G.P. L.P.: 6.8% (Schedule 13G, filed Apr 16, 2026)
- SANOFI: 5.7% (Schedule 13G, filed May 6, 2026)
- Redmile Group, LLC: 5.6% (Schedule 13G, filed May 15, 2026)
- Cormorant Asset Management, LP: 5.0% (Schedule 13G, filed May 15, 2026)